Dongbao Pharma to Build $59 Million Insulin Manufacturing Facility

Tonghua Dongbao Pharma announced plans to spend $59 million to build a new plant to manufacture insulin API and insulin products. Although China's insulin market is dominated by western pharmas, Dongbao was the largest domestic producer with a 16% share in 2012 (Novo Nordisk took 60%). Dongbao makes insulin APIs, prefilled syringes and insulin pen-cartridges. More details.... Stock Symbols: (SHA: 600867) Share this with colleagues: // //